Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

PRE-MARKET MOVERS: Stitch Fix shoots higher in pre-market, but Lam Research Corp lags

Retailer Zumiez Inc and diabetes- focuse manufacturer Novo Nordisk were also in the frame

As US equity markets are poised for a lower start, a notable exception pre-market deals was Stitch Fix Inc (NASDAQ:SFIX), which surged over 9% to US$21.51.

It came after the online stylist unveiled strong earnings and user growth in its latest quarter.

Earnings for the three months came in at US$0.09 against consensus forecasts of US$0.03.

Meanwhile, revenue was US$ 316.7mln against the US$306mln forecast and active clients came in at 2.7mln against an estimate of 2.66mln.

Stitch fix blows out Wall Street’s expectations and announces the launch of Stitch Fix Kids https://t.co/LEBLPHOFSg by @mattlynley pic.twitter.com/xcQvmUA0Gy

— TechCrunch (@TechCrunch) 7 June 2018

Elsewhere, semiconductor-equipment company Lam Research Corp (NASDAQ:LRCX) dropped 5.4% to US$188.83 on the back of an analyst note.

Evercore ISI analyst C.J. Muse said there were "risks" to Lam's second- and third-quarter shipments. He rates shares outperform though and has a target price of US$300.

Zumiez Inc (NASDAQ:ZUMZ) shares surged almost 15% in pre-market to US$31 after the clothing firm posted a narrower than expected quarterly loss.

The group posted a loss of US$0.10 against analyst projections for a loss of US$0.12.

Sales rose 14% to US$206.3mln against consensus of US$199mln.

Shares in Novo Nordisk (NYSE:NVO) opened around 3% lower before the New York bell after the world's largest diabetes drugs company is reportedly considering cutting up to 3,000 staff and dropping its long-term financial targets.

Drug manufacturers face new US legislation aimed at reining in high drug prices.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK